Protein tyrosine phosphatases in multiple myeloma

Pegah Abdollahi; Maja Köhn; Magne Børset

doi:10.1016/j.canlet.2020.11.042

Protein tyrosine phosphatases in multiple myeloma

Cancer Lett. 2021 Mar 31:501:105-113. doi: 10.1016/j.canlet.2020.11.042. Epub 2020 Dec 5.

Authors

Pegah Abdollahi¹, Maja Köhn², Magne Børset³

Affiliations

¹ Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Clinic of Medicine, St. Olavs Hospital, Trondheim, Norway; Faculty of Biology, Institute of Biology III, University of Freiburg, 79104, Freiburg, Germany; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, 79104, Freiburg, Germany. Electronic address: Pegah.abdollahi@ntnu.no.
² Faculty of Biology, Institute of Biology III, University of Freiburg, 79104, Freiburg, Germany; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, 79104, Freiburg, Germany. Electronic address: maja.koehn@bioss.uni-freiburg.de.
³ Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Department of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, Norway. Electronic address: Magne.borset@ntnu.no.

PMID: 33290866
DOI: 10.1016/j.canlet.2020.11.042

Abstract

Many cell signaling pathways are activated or deactivated by protein tyrosine phosphorylation and dephosphorylation, catalyzed by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), respectively. Even though PTPs are as important as PTKs in this process, their role has been neglected for a long time. Multiple myeloma (MM) is a cancer of plasma cells, which is characterized by production of monoclonal immunoglobulin, anemia and destruction of bone. MM is still incurable with high relapse frequency after treatment. In this review, we highlight the PTPs that were previously described in MM or have a role that can be relevant in a myeloma context. Our purpose is to show that despite the importance of PTPs in MM pathogenesis, many unanswered questions in this field need to be addressed. This might help to detect novel treatment strategies for MM patients.

Keywords: CD45 (PTPRC); Dual specificity phosphatase (DUSP); PRL-3 (PTP4A3); SHP1 (PTPN6); SHP2 (PTPN11).

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Multiple Myeloma / enzymology*
Protein Tyrosine Phosphatases / metabolism*

Substances

Protein Tyrosine Phosphatases